Pro­to­cols: Al­ler­gan diss­es gi­ant leaps, con­cen­trates on step­ping stones; As­traZeneca al­so gets a boost from Bris­tol-My­ers’ woes

Al­ler­gan made it of­fi­cial to­day. It is not look­ing for any kind of trans­for­ma­tion­al ac­qui­si­tions, so you can put those ru­mors aside and for­get about any big bid for Bio­gen. Now that it has com­plet­ed the sale of its gener­ics biz to Te­va, though, look for CEO Brent Saun­ders to spend bil­lions on “step­ping stone” deals, ac­cord­ing to Ever­core ISI’s Umer Raf­fat. That means more add-ons to the pipeline, where he’s been busy since the Pfiz­er megamerg­er failed to pan out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER